Skip to main content

Military Health System

Incident COVID-19 Infections, Active and Reserve Components, Jan. 1, 2020–Aug. 31, 2021

Image of U.S. Marines with Marine Rotational Force - Darwin receive a second COVID-19 test during quarantine on Royal Australian Air Force Base Darwin in Darwin, NT, Australia, June 12, 2020. The COVID-19 test was administered to each Marine after arriving from California. All Marines will be quarantined for 14 days and undergo an additional test before quarantine release. No Marines tested positive for COVID-19. The U.S. Marine Corps and Australian Defence Force service members are working together to ensure the safety of the local community. (U.S. Marine Corps photo by Lance Cpl. Natalie Greenwood). U.S. Marines with Marine Rotational Force - Darwin receive a second COVID-19 test during quarantine on Royal Australian Air Force Base Darwin in Darwin, NT, Australia, June 12, 2020. The COVID-19 test was administered to each Marine after arriving from California. All Marines will be quarantined for 14 days and undergo an additional test before quarantine release. No Marines tested positive for COVID-19. The U.S. Marine Corps and Australian Defence Force service members are working together to ensure the safety of the local community. (U.S. Marine Corps photo by Lance Cpl. Natalie Greenwood)

Recommended Content:

Medical Surveillance Monthly Report

What are the New findings?

This study describes the characteristics of COVID-19 cases among U.S. service members to date, including the prevalence of pre-existing comorbidities, vaccination status, and the proportion of cases hospitalized. This report also describes the characteristics of service members who died from COVID-19 during the surveillance period.

What is the Impact on Readiness and Force Health Protection?

Detailed data on demographic characteristics, underlying medical conditions, and vaccination status can inform targeted communication to encourage persons in at-risk groups to practice preventive measures and promptly seek medical care if they become ill. Enhanced surveillance efforts can enable actions to prevent and control the current COVID-19 epidemic, which threatens the health of the force.

Abstract

Between Jan. 1, 2020 and Aug. 31, 2021, a total of 189,239 service members were identified as confirmed or probable cases of COVID-19. The majority of cases were male (81.2%) and 57.3% were aged 20–29 years. Overall, 19.2% had a diagnosis of at least 1 of the pre-existing comorbidities of interest in the year prior to becoming a case. The most common pre-existing comorbidity was obesity or overweight (5.2%), followed by cardiovascular disease (4.2%), and substance use disorder including nicotine dependence (4.0%). Service members who were hospitalized for COVID-19 were twice as likely to have a diagnosis of any pre-existing comorbidity compared to those who were not hospitalized. There were a total of 1,760 hospitalizations (0.9%) and 45 deaths reported among service members. In addition, there were 11,899 cases observed among fully vaccinated individuals; however, only 0.4% of hospitalized cases were fully vaccinated and no service member deaths occurred among fully vaccinated individuals during the surveillance period, highlighting the importance of COVID-19 vaccination for force health protection.

Background

Since the beginning of the COVID-19 pandemic, there have been over 249 million COVID-19 cases and 5 million COVID-related deaths worldwide, including over 46 million cases and over 754 thousand deaths in the U.S.1 Although most symptomatic cases of COVID-19 are mild, severe disease occurs in any demographic group.2,3 Older individuals and those with underlying medical conditions are at higher risk of serious illness and death; this risk increases with advancing age.3 The majority of COVID-19 deaths occur among adults aged 60 or older and among persons with serious underlying health conditions such as cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), heart conditions (e.g., heart failure, coronary artery disease, cardiomyopathies), an immunocompromised state from solid organ transplant, and obesity (body mass index [BMI]=30–39.9 kg/m2).4,5

Two mRNA vaccines for COVID-19 (Moderna and Pfizer-BioNTech) were approved in December 2020 and an adenovirus-vectored vaccine (Janssen) was approved in late February 2021. Randomized clinical trials have shown that the current mRNA-based COVID-19 vaccines have high efficacies (94%–95%) for preventing COVID-19.6,7 The Janssen adenovirus vectored vaccine also had moderately high efficacy against symptomatic COVID-19 (66%) and high efficacy against hospitalization for COVID-19 (93%).8,9 Since these vaccines became available and used in the U.S., they have had substantial impacts on mitigating COVID-19 outbreaks and reducing risk of hospitalization and death.10 Concerns were initially raised about the effectiveness of these vaccines against emerging new strains of SARS-CoV-2, including the Delta (B.1.617.2) variant, which became the predominant variant of the virus in the U.S. in July 2021.12 There is currently very limited information about real-world effectiveness of the Janssen vaccine against the Delta variant. However, several studies have indicated moderate to high effectiveness of the Moderna and Pfizer-BioNTech vaccines against the Delta variant, particularly for preventing hospitalization and death.12–14

The Department of Defense (DOD) began COVID-19 vaccination in mid-December 2020. These vaccines were originally made available to service members on a voluntary basis according to occupational risk, but were made mandatory on 24 August 2021.15 The objective of this study was to provide an update on the numbers of probable and confirmed COVID-19 cases among U.S. military service members in addition to describing demographics, prevalence of pre-existing comorbidities, hospitalization rates, and deaths.

Methods

Since March 2020, the Armed Forces Health Surveillance Division (AFHSD) has maintained a case list of MHS beneficiaries with COVID-19. This list is updated daily and comprises Composite Health Care System (CHCS) Health Level 7 (HL7)-formatted and MHS Genesis laboratory positive test results extracted by the Navy and Marine Corps Public Health Center Epi Data Center (for all services), as well as medical event reports of laboratory confirmed and probable COVID-19 infection derived from the Disease Reporting System Internet (DRSi). AFHSD also maintains the Defense Medical Surveillance System (DMSS), a continuously expanding relational database of personnel and medical data.

For this analysis, cases of COVID-19 among active and reserve/guard component service members were included if the incident date occurred within 90 days of a personnel demographic record maintained in the DMSS. Beneficiary status (i.e., active or reserve/guard component) and branch of military service were determined based on the information recorded in the DMSS. The incident date for each COVID-19 case was defined as the earliest date of onset recorded in the DRSi, or the earliest collection date for the sample that tested positive via PCR or antigen laboratory testing.

In addition, DMSS data were used to identify hospitalizations for COVID-19 and for demographic information that was missing from the case list. DMSS data were also used to identify comorbidities from administrative records of inpatient and outpatient medical encounters, which included encounters from fixed military treatment facilities as well as outsourced care reimbursed by TRICARE. A hospitalization for COVID-19 was defined by having an inpatient record in DMSS occurring within 30 days after the first case record for COVID-19, with the International Classification of Diseases, 10th Revision (ICD-10) code U07.1 in the first or second diagnostic position, or a diagnosis of COVID-like illness in the first or second diagnostic position (Table 1). An individual was considered to have a pre-existing comorbidity if there was an inpatient or outpatient encounter record containing an ICD-10 code for a comorbidity of interest within 365 days prior to the COVID-19 incident date (Table 2). 

Data on vaccination status at the time of the incident COVID-19 infection were derived from immunization records in the DMSS. An individual was considered fully vaccinated at the time of the case if the incident date occurred at least 14 days after the second dose of the Moderna (vaccine administered [CVX] code=207) or Pfizer-BioNTech (CVX code=208) vaccine, or at least 14 days after the first dose of the Janssen vaccine (CVX code=212). An individual was considered partially vaccinated if the individual had received at least 1 dose of vaccine but did not meet the aforementioned 14-day criteria for full vaccination. 

COVID-19-related deaths occurring among service members were tracked and reported separately from cases of COVID-19. These deaths were identified via communication with the Armed Forces Medical Examiner System and via media reports, Director's Critical Information Requirement reports, the DRSi, and chart review of service members' electronic health record in the Armed Forces Health Longitudinal Technology Application (AHLTA). Information documented in these sources were used to describe pre-existing comorbidities and clinical course among those who died from COVID-19.

Results

As of Aug. 31, 2021, a total of 189,239 service members were identified as confirmed or probable cases of COVID-19 (Table 3). Of these cases, 19.2% had a medical encounter for at least 1 of the pre-existing comorbidities of interest in the year prior to becoming a case, and 6.9% had an encounter for 2 or more pre-existing comorbidities. There were a total of 1,760 hospitalizations (0.9%) and 45 deaths. Of the 42 deaths with past medical history data available for review, 17 (40.5%) had 1 pre-existing comorbidity of interest, 15 (35.7%) had 2 or more comorbidities and 10 (23.8%) had no comorbidities. A total of 111,801 cases occurred after COVID-19 vaccinations became available to the DOD on 11 December 2020. Among these cases, 83.7% (n=93,616) occurred among unvaccinated service members, 10.6% (n=11,899) cases occurred among fully vaccinated individuals, and 5.6% (n=6,286) occurred among partially vaccinated individuals. A total of 48 hospitalizations for COVID-19 occurred among fully vaccinated service members and there were 44 hospitalizations among partially vaccinated service members (data not shown). No service member deaths occurred among vaccinated individuals, except for 1 active duty member who had received 1 dose of Pfizer vaccine 18 days prior to his death.

Service members who were hospitalized for COVID-19 were twice as likely to have a diagnosis of any comorbidity in the year prior to becoming a case compared to those who were not hospitalized, and almost 3 times as likely to have a diagnosis of multiple comorbidities (Table 4). Of note, those who were hospitalized were 5 times as likely to have a prior diagnosis of chronic liver disease and almost 4 times as likely to have a prior hypertension diagnosis, compared to those who were not hospitalized. Of the 32 service member deaths with hospitalization data available, 24 (75.0%) were hospitalized at the time of death, 8 (25.0%) were found unresponsive at home or at an alternate site, and 1 died en route to the hospital.

The highest peak in the number of past 14-day incident COVID-19 cases among all service members occurred on Jan. 15, 2021 with a total of 16,418 past 14-day cases, and was preceded by a peak on Dec. 11, 2020 of 11,131 past 14-day cases (Figure). Following the peak on Jan. 15, 2021, there was another peak on Aug. 25, 2021 of 9,875 past 14-day cases coinciding with the period of transmission of the Delta variant.

Active component

A total of 163,171 active component members had been infected with the SARS-CoV-2 virus as of 31 August 2021 (Table 3). The largest demographic proportions of cases were among those who were male (81.6%), aged 20–24 (37.5%), non-Hispanic White (51.0%), and in the Army (42.0%). About one-fifth (19.9%) of the infected cases had a diagnosis of a pre-existing comorbidity in the year prior to becoming a case, and 7.0% were diagnosed with 2 or more comorbidities. Of the comorbidities that were assessed, the most commonly diagnosed were obesity or overweight (n= 8,690; 5.3%), substance use including nicotine dependence (n= 7,191; 4.4%), and cardiovascular disease (n= 6,840; 4.2%). A total of 1,504 active component members (0.9%) were hospitalized, with a median hospital stay of 4 days (interquartile range [IQR]=2–6). A total of 10,731 cases (11.1%) among the 96,539 cases that occurred after Dec. 11, 2020 were fully vaccinated, and 5.6% (n=5,396) were partially vaccinated.

During the surveillance period, there were 17 deaths among active component COVID-19 cases (data not shown). Past medical history was available in AHLTA for all of the active component service member deaths reviewed. COVID-specific case-related information, including clinical progression of illness, was available for review in 12 (70.6%) AHLTA records and 17 (100.0%) corroborative clinical reports and summaries, typically prepared by the services following a death. Of the active component deaths, 7 (41%) were Army, 7 (41%) were Navy, 2 (12%) were Air Force, and 1 (6%) was Marine Corps. The average age at death was 39 years. A majority (82.4%; n=14) of those who died had at least 1 comorbidity of interest and 52.9% (n=9) had a BMI that placed them in the overweight or obese category. The 2 most common pre-existing comorbidities among those who died were obesity (52.9%; n=9) and cardiovascular disease, primarily hyperlipidemia (23.5%, n=4). At the time of death, 11 service members were hospitalized, 4 were "found unresponsive" at home or at an alternative site and later pronounced dead in the emergency room, and 1 died en route to the hospital. Hospitalization data for 1 service member was not available. The clinical progression of illness for most hospitalized cases followed a standard pattern of deterioration: onset of symptomatic illness, increasing dyspnea (shortness of breath) with development of COVID pneumonia, ICU admission; onset of acute respiratory distress syndrome (ARDS) followed by intubation and mechanical ventilation, development of COVID-related complications (e.g., cardiogenic shock, myocarditis, deep vein thrombosis, disseminated intravascular coagulation, etc.) and death. None of the active component service members who died were fully vaccinated.

Reserve/Guard component

A total of 26,068 COVID-19 cases were identified among reserve and guard service members (Table 3). The largest proportions of cases were male (79.1%), aged 20–24 (21.5%), non-Hispanic White (55.7%), and in the Army (68.9%). About one-seventh (14.3%) of cases were diagnosed with a pre-existing comorbidity, and 6.5% were diagnosed with 2 or more comorbidities. Of the pre-existing comorbidities that were assessed, the most commonly diagnosed comorbidities were obesity or overweight (n=1,104; 4.2%), cardiovascular disease (n=1,079; 4.1%), and neoplasms (n=884; 3.4%). A total of 256 reserve/guard members (1.0%) were hospitalized, with a median hospital stay of 4 days (IQR=2.5–7). A total of 1,168 cases (7.7%) among the 15,262 cases that occurred after Dec. 11, 2020 were fully vaccinated, and 5.8% (n=890) were partially vaccinated.

There were 28 deaths among reserve and guard COVID-19 cases; of these, 8 were on active duty status at the time of death (data not shown). Past medical history was available in AHLTA for 25 (89.3%) of the reserve/guard deaths reviewed. COVID-specific case-related information, including clinical progression of illness, was available in AHLTA and corroborative clinical reports/summaries for all of the reserve/guard members who died while on active duty, but only available for 5 (25%) reserve/guard members who died while not on active duty. Similarly, vaccination status was available for all of the activated reserve/guard members who died, but only available for 11 (55%) of the inactivated reserve/guard members who died. Of the total reserve guard deaths, 19 (67.9%) were Army, 5 (17.9%) were Navy, and 4 (14.3%) were Air Force. The average age at death was 47 years. Of those with available data in AHLTA or in other sources, 15 (62.2%; 15/23) had at least 1 pre-existing comorbidity and 12 (54.5%; 12/22) had BMIs that placed them in the category of overweight or obese. Similar to the active component, the most common comorbidities among reserve/guard deaths were obesity (54.5%) and cardiovascular disease (25.0%; 6/24), with 4 having a diagnosis of hyperlipidemia. Of the 11 inactive reserve/guard service members with available COVID-specific case-related data, 8 (72.7%) were hospitalized at the time of death with a clinical progression of illness that followed the standard pattern outlined above and 3 (27.3%) were found unresponsive at home or at an alternate site and later pronounced dead in the emergency room. None of the reserve/guard service members who died were fully vaccinated.

Editorial Comment

This report describes the demographic characteristics and prevalence of pre-existing comorbidities among service members with incident COVID-19 infection. Not surprisingly, cases among service members (including recruits) were most commonly diagnosed in young, non-Hispanic White males, which follows the expected demographic distributions of these groups. Overall, 19.2% had a medical encounter for at least 1 of the pre-existing comorbidities of interest in the year prior to becoming a case. The most common pre-existing comorbidities in both hospitalized and non-hospitalized cases were obesity or overweight, followed by cardiovascular disease. These same pre-existing comorbidities were also common among service members who died from COVID-19.

For each of the comorbidities evaluated in this study, hospitalized COVID-19 cases were more likely than non-hospitalized cases to have had a medical encounter for the condition in the past year. Chronic liver disease, hypertension, and chronic kidney disease were among the comorbidities most likely to be previously diagnosed in the hospitalized cases compared to the non-hospitalized cases. The finding that chronic liver disease was more likely to be diagnosed in hospitalized compared to non-hospitalized cases is noteworthy because recent studies have suggested that chronic liver disease is not a significant comorbid condition for COVID-19.16,17 However, other studies have indicated that cirrhosis increases risk for COVID-19 hospitalization and death among patients with chronic liver disease, and that cirrhosis may play a role in immune dysfunction.18,19

There were totals of 1,760 hospitalizations (0.9%) and 45 deaths among service members as of Aug. 31, 2021. Although there were 11,899 cases of COVID-19 occurring among fully vaccinated individuals, only 0.4% of hospitalized cases were fully vaccinated and no service member deaths occurred among fully vaccinated individuals, highlighting the importance of COVID-19 vaccination for force health protection. In particular, 45 deaths corresponds to a cumulative case fatality ratio of about 0.02% (i.e., 1 death per 4,205 infected), which is much lower than the case fatality ratio of 1.6% observed in the general U.S. population.20 This lower case fatality ratio is not surprising given that service members are on average younger and healthier compared to members of the general U.S. population. 

It should be noted that the progression of illness followed a standard clinical course for a majority of service members who died from COVID-19 during the surveillance period.21 However, there were a few individuals who experienced rapid deterioration after having been discharged from the hospital and some who died suddenly at home or at an alternate site with COVID symptoms or a previously diagnosed COVID-19 infection. Acute respiratory and thrombotic complications of COVID-19 have been previously reported as common causes of death, with many patients having comorbidities such as hypertension, ischemic heart disease, and obesity.22 In patients who die suddenly, severe systemic inflammation, multi-organ dysfunction, and cardiovascular failure may also play a role.23–25 It is important to note that, although service members are a generally young and healthy population experiencing few deaths due to COVID-19, they are still vulnerable to the harmful effects of this disease particularly if they have pre-existing comorbidities and are unvaccinated.

There are several limitations that should be considered when interpreting the results of this study. First, the prevalence of pre-existing comorbidities among all cases may be underestimated because medical encounter data were queried in the year prior to the incident date of the case. Individuals who did not seek medical care for these conditions during this time period would not be captured. However, comorbidities may also be overestimated because the case definition allowed for only a single medical encounter to qualify as a comorbidity; therefore, screening encounters that were miscoded using the diagnosis code for that condition may overestimate the occurrence of certain pre-existing comorbidities. Importantly, as the science evolves more is being learned about the types of medical conditions that place individuals at higher risk for severe illness from COVID-19. The list of comorbidities investigated in this analysis is not exhaustive and should be re-evaluated in subsequent investigations. Second, the expansion of MHS Genesis to military treatment facilities throughout most of the western U.S. presented challenges to linking MHS GENESIS laboratory records with case information in the DRSi and the CHCS. As a result, some cases may have been missed. Finally, the number of cases, vaccination information, and hospitalization status may have also been underestimated if individuals were seen for care outside of the MHS TRICARE network, which is most likely to occur among inactivated reserve/guard members.

The COVID-19 pandemic continues to have persistent person-to-person spread in the community worldwide and will require continuous monitoring as new variants of the SARS-CoV-2 virus emerge. Findings presented here draw attention to the necessity of building on present-day disease surveillance efforts to collect and analyze case prevalence data, and in particular data including vaccination status, hospitalization, death, and serious underlying health conditions. Continued surveillance of COVID-19 among service members remains an important part of force health protection efforts.

References

1. Johns Hopkins University Coronavirus Resource Center. Mortality Analyses. Updated 6 November 2021. Accessed 6 November 2021. https://coronavirus.jhu.edu/map.html

2. The Novel Coronavirus Pneumonia Emergency Response Epidemiology. The Epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. China CDC Weekly. 2020;2(8):113–122.

3. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—U.S., February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343–346.

4. Centers for Disease Control and Prevention. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—U.S., February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382–386.

5. Centers for Disease Control and Prevention. People who are at increased risk for severe illness with certain medical conditions. Accessed 11 November 2021. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html

6. Polack FP, Thomas SJ, Kitchen N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.

7. Baden LR El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384(5):403–416.

8. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201.

9. Oliver SE, Gargano JW, Scobie H, et al. The Advisory Committee on Immunizations Practises’ interim recommendation for use of the Janssen COVID-19 vaccine – United States, February 2021. MMWR. 2021;70(9):329–332.

10. Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on COVID-19 outbreaks in the United States. Clin Infect Dis. 2021;ciab079.

11. Centers for Disease Control and Prevention. Delta Variant: What We Know About the Science. Accessed 11 November 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html.

12. Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;s41591-021-01583-4.

13. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585–594. 

14. Tenforde MW, Self WH, Naioti EA, et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1156–1162.

15. Department of Defense. Deputy Secretary of Defense. Memo: Mandatory coronavirus disease 2019 vaccination of Department of Defense service members. 21 August 2021. Accessed 11 November 2021. https://media.defense.gov/2020/Dec/08/2002548508/-1/-1/0/CORONAVIRUS-DISEASE-2019-VACCINE-GUIDANCE.PDF

16. Lippi G, de Oliveira MHS, Henry BM. Chronic liver disease is not associated with severity or mortality in Coronavirus disease 2019 (COVID-19): A pooled analysis. Eur J Gastroenterol Hepatol. 2021;33(1):114–115.

17. Lin, J., Bao, B., Khurram, N.A. et al. Chronic liver disease not a significant comorbid condition for COVID-19. Sci Rep. 2021;11(1):11734.

18. Sharma P, Kumar A, Anikhindi S, et al. Effect of COVID-19 on Pre-existing Liver disease: What Hepatologist Should Know? J Clin Exp Hepatol. 2021;11(4):484–493. 

19. Marjot T, Webb GJ, Barritt AS 4th, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18(5):348–364. 

20. Johns Hopkins University Coronavirus Resource Center. Mortality Analyses. Updated 11 November 2021. Accessed 11 November 2021. https://coronavirus.jhu.edu/data/mortality

21. Cates J, Lucero-Obusan C, Dahl RM, et al. Risk for In-Hospital Complications Associated with COVID-19 and Influenza - Veterans Health Administration, United States, October 1, 2018-May 31, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(42):1528–1534.  

22. Elezkurtaj S, Greuel S, Ihlow J, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021;11(1):4263. 

23. Yang N, Tian K, Jin M, et al. Sudden death of COVID-19 patients in Wuhan, China: A retrospective cohort study. J Glob Health. 2021;11:05006. 

24. Polat V, Bostancı Gİ. Sudden death due to acute pulmonary embolism in a young woman with COVID-19. J Thromb Thrombolysis. 2020;50(1):239–241. 

25. Giudicessi JR. Excess out-of-hospital sudden deaths during the COVID-19 pandemic: A direct or indirect effect of SARS-CoV-2 infections? Heart Rhythm. 2021;18(2):219–220.

FIGURE. Past 14-day COVID-19 cases, active and reserve components, U.S. Armed Forces, 1 January 2020–31 August 2021

 

TABLE 1. ICD-10 codes used to identify hospitalizations for COVID-19

TABLE 2. ICD-10 codes used to identify comorbidities

TABLE 3. COVID-19 confirmed and probable cases, active and reserve components, U.S. Armed Forces, 1 January 2020–31 August 2021

TABLE 3 (cont) . COVID-19 confirmed and probable cases, active and reserve components, U.S. Armed Forces, 1 January 2020–31 August 2021

TABLE 4. Pre-existing comorbidities by hospitalization status, active and reserve components, U.S. Armed Forces, 1 January 2020–31 August 2021

You also may be interested in...

Testosterone Replacement Therapy Use Among Active Component Service Men, 2017

Article
3/1/2019
Image of Marines carrying a wooden log for physical fitness. Click to open a larger version of the image.

This analysis summarizes the prevalence of testosterone replacement therapy (TRT) during 2017 among active component service men by demographic and military characteristics. This analysis also determines the percentage of those receiving TRT in 2017 who had an indication for receiving TRT using the 2018 American Urological Association (AUA) clinical practice guidelines. In 2017, 5,093 of 1,076,633 active component service men filled a prescription for TRT, for a period prevalence of 4.7 per 1,000 male service members. After adjustment for covariates, the prevalence of TRT use remained highest among Army members, senior enlisted members, warrant officers, non-Hispanic whites, American Indians/Alaska Natives, those in combat arms occupations, healthcare workers, those who were married, and those with other/unknown marital status. Among active component male service members who received TRT in 2017, only 44.5% met the 2018 AUA clinical practice guidelines for receiving TRT.

Recommended Content:

Medical Surveillance Monthly Report

Brief Report: Male Infertility, Active Component, U.S. Armed Forces, 2013–2017

Article
3/1/2019
Sperm is the male reproductive cell  Photo: iStock

Infertility, defined as the inability to achieve a successful pregnancy after 1 year or more of unprotected sexual intercourse or therapeutic donor insemination, affects approximately 15% of all couples. Male infertility is diagnosed when, after testing both partners, reproductive problems have been found in the male. A male factor contributes in part or whole to about 50% of cases of infertility. However, determining the true prevalence of male infertility remains elusive, as most estimates are derived from couples seeking assistive reproductive technology in tertiary care or referral centers, population-based surveys, or high-risk occupational cohorts, all of which are likely to underestimate the prevalence of the condition in the general U.S. population.

Recommended Content:

Medical Surveillance Monthly Report

Sexually Transmitted Infections, Active Component, U.S. Armed Forces, 2010–2018

Article
3/1/2019
Anopheles merus

This report summarizes incidence rates of the 5 most common sexually transmitted infections (STIs) among active component service members of the U.S. Armed Forces during 2010–2018. Infections with chlamydia were the most common, followed in decreasing order of frequency by infections with genital human papillomavirus (HPV), gonorrhea, genital herpes simplex virus (HSV), and syphilis. Compared to men, women had higher rates of all STIs except for syphilis. In general, compared to their respective counterparts, younger service members, non-Hispanic blacks, soldiers, and enlisted members had higher incidence rates of STIs. During the latter half of the surveillance period, the incidence of chlamydia and gonorrhea increased among both male and female service members. Rates of syphilis increased for male service members but remained relatively stable among female service members. In contrast, the incidence of genital HPV and HSV decreased among both male and female service members. Similarities to and differences from the findings of the last MSMR update on STIs are discussed.

Recommended Content:

Medical Surveillance Monthly Report

Outbreak of Acute Respiratory Illness Associated with Adenovirus Type 4 at the U.S. Naval Academy, 2016

Article
2/1/2019
Malaria case definition

Human adenoviruses (HAdVs) are known to cause respiratory illness outbreaks at basic military training (BMT) sites. HAdV type-4 and -7 vaccines are routinely administered at enlisted BMT sites, but not at military academies. During August–September 2016, U.S. Naval Academy clinical staff noted an increase in students presenting with acute respiratory illness (ARI). An investigation was conducted to determine the extent and cause of the outbreak. During 22 August–11 September 2016, 652 clinic visits for ARI were identified using electronic health records. HAdV-4 was confirmed by real-time polymerase chain reaction assay in 18 out of 33 patient specimens collected and 1 additional HAdV case was detected from hospital records. Two HAdV-4 positive patients were treated for pneumonia including 1 hospitalized patient. Molecular analysis of 4 HAdV-4 isolates identified genome type 4a1, which is considered vaccine-preventable. Understanding the impact of HAdV in congregate settings other than enlisted BMT sites is necessary to inform discussions regarding future HAdV vaccine strategy.

Recommended Content:

Medical Surveillance Monthly Report

Update: Incidence of Glaucoma Diagnoses, Active Component, U.S. Armed Forces, 2013–2017

Article
2/1/2019
Glaucoma

Glaucoma is an eye disease that involves progressive optic nerve damage and vision loss, leading to blindness if undetected or untreated. This report describes an analysis using the Defense Medical Surveillance System to identify all active component service members with an incident diagnosis of glaucoma during the period between 2013 and 2017. The analysis identified 37,718 incident cases of glaucoma and an overall incidence rate of 5.9 cases per 1,000 person-years (p-yrs). The majority of cases (97.6%) were diagnosed at an early stage as borderline glaucoma; of these borderline cases, 2.2% progressed to open-angle glaucoma during the study period. No incident cases of absolute glaucoma, or total blindness, were identified. Rates of glaucoma were higher among non-Hispanic black (11.0 per 1,000 p-yrs), Asian/Pacific Islander (9.5), and Hispanic (6.9) service members, compared with non-Hispanic white (4.0) service members. Rates among female service members (6.6 per 1,000 p-yrs) were higher than those among male service members (5.8). Between 2013 and 2017, incidence rates of glaucoma diagnoses increased by 75.4% among all service members.

Recommended Content:

Medical Surveillance Monthly Report

Re-evaluation of the MSMR Case Definition for Incident Cases of Malaria

Article
2/1/2019
Anopheles merus

The MSMR has been publishing the results of surveillance studies of malaria since 1995. The standard MSMR case definition uses Medical Event Reports and records of hospitalizations in counting cases of malaria. This report summarizes the performance of the standard MSMR case definition in estimating incident cases of malaria from 2015 through 2017. Also explored was the potential surveillance value of including outpatient encounters with diagnoses of malaria or positive laboratory tests for malaria in the case definition. The study corroborated the relative accuracy of the MSMR case definition in estimating malaria incidence and provided the basis for updating the case definition in 2019 to include positive laboratory tests for malaria antigen within 30 days of an outpatient diagnosis.

Recommended Content:

Medical Surveillance Monthly Report

Update: Malaria, U.S. Armed Forces, 2018

Article
2/1/2019
Anopheles merus

Malaria infection remains an important health threat to U.S. service mem­bers who are located in endemic areas because of long-term duty assign­ments, participation in shorter-term contingency operations, or personal travel. In 2018, a total of 58 service members were diagnosed with or reported to have malaria. This represents a 65.7% increase from the 35 cases identi­fied in 2017. The relatively low numbers of cases during 2012–2018 mainly reflect decreases in cases acquired in Afghanistan, a reduction due largely to the progressive withdrawal of U.S. forces from that country. The percentage of cases of malaria caused by unspecified agents (63.8%; n=37) in 2018 was the highest during any given year of the surveillance period. The percent­age of cases identified as having been caused by Plasmodium vivax (10.3%; n=6) in 2018 was the lowest observed during the 10-year surveillance period. The percentage of malaria cases attributed to P. falciparum (25.9 %) in 2018 was similar to that observed in 2017 (25.7%), although the number of cases increased. Malaria was diagnosed at or reported from 31 different medical facilities in the U.S., Afghanistan, Italy, Germany, Djibouti, and Korea. Pro­viders of medical care to military members should be knowledgeable of and vigilant for clinical manifestations of malaria outside of endemic areas.

Recommended Content:

Medical Surveillance Monthly Report

Thyroid Disorders, Active Component, U.S. Armed Forces, 2008–2017

Article
12/1/2018

This analysis describes the incidence and prevalence of five thyroid disorders (goiter, thyrotoxicosis, primary/not otherwise specified [NOS] hypothyroidism, thyroiditis, and other disorders of the thyroid) among active component service members between 2008 and 2017. During the 10-year surveillance period, the most common incident thyroid disorder among male and female service members was primary/NOS hypothyroidism and the least common were thyroiditis and other disorders of thyroid. Primary/NOS hypothyroidism was diagnosed among 8,641 females (incidence rate: 43.7 per 10,000 person-years [p-yrs]) and 11,656 males (incidence rate: 10.2 per 10,000 p-yrs). Overall incidence rates of all thyroid disorders were 3 to 5 times higher among females compared to males. Among both males and females, incidence of primary/NOS hypothyroidism was higher among non-Hispanic white service members compared with service members in other race/ethnicity groups. The incidence of most thyroid disorders remained stable or decreased during the surveillance period. Overall, the prevalence of most thyroid disorders increased during the first part of the surveillance period and then either decreased or leveled off.31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Incidence and Prevalence of the Metabolic Syndrome Using ICD-9 and ICD-10 Diagnostic Codes, Active Component, U.S. Armed Forces, 2002–2017

Article
12/1/2018

This report uses ICD-9 and ICD-10 codes (277.7 and E88.81, respectively) for the metabolic syndrome (MetS) to summarize trends in the incidence and prevalence of this condition among active component members of the U.S. Armed Forces between 2002 and 2017. During this period, the crude overall incidence rate of MetS was 7.5 cases per 100,000 person-years (p-yrs). Compared to their respective counterparts, overall incidence rates were highest among Asian/Pacific Islanders, Air Force members, and warrant officers and were lowest among those of other/unknown race/ethnicity, Marine Corps members, and junior enlisted personnel and officers. During 2002–2017, the annual incidence rates of MetS peaked in 2009 at 11.6 cases per 100,000 p-yrs and decreased to 5.9 cases per 100,000 p-yrs in 2017. Annual prevalence rates of MetS increased steadily during the first 11 years of the surveillance period reaching a high of 38.9 per 100,000 active component service members in 2012, after which rates declined slightly to 31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Adrenal Gland Disorders, Active Component, U.S. Armed Forces, 2002–2017

Article
12/1/2018

During 2002–2017, the most common incident adrenal gland disorder among male and female service members was adrenal insufficiency and the least common was adrenomedullary hyperfunction. Adrenal insufficiency was diagnosed among 267 females (crude overall incidence rate: 8.2 cases per 100,000 person-years [p-yrs]) and 729 males (3.9 per 100,000 p-yrs). In both sexes, overall rates of other disorders of adrenal gland and Cushing’s syndrome were lower than for adrenal insufficiency but higher than for hyperaldosteronism, adrenogenital disorders, and adrenomedullary hyperfunction. Crude overall rates of adrenal gland disorders among females tended to be higher than those of males, with female:male rate ratios ranging from 2.1 for adrenal insufficiency to 5.5 for androgenital disorders and Cushing’s syndrome. The highest overall rates of adrenal insufficiency for males and females were among non-Hispanic white service members. Among females, rates of Cushing’s syndrome and other disorders of adrenal gland were 31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

2018 #ColdReadiness Twitter chat recap: Preventing cold weather injuries for service members and their families

Fact Sheet
2/5/2018

To help protect U.S. armed forces, the Armed Forces Health Surveillance Branch (AFHSB) hosted a live #ColdReadiness Twitter chat on Wednesday, January 24th, 12-1:30 pm EST to discuss what service members and their families need to know about winter safety and preventing cold weather injuries as the temperatures drop. This fact sheet documents highlights from the Twitter chat.

Recommended Content:

Medical Surveillance Monthly Report | Winter Safety | Medical and Dental Preventive Care Fitness | Health Readiness & Combat Support

Demographic and Military Traits of Service Members Diagnosed as Traumatic Brain Injury Cases

Fact Sheet
3/30/2017

This fact sheet provides details on the demographic and military traits of service members diagnosed as traumatic brain injury (TBI) cases during a 16-year surveillance period from 2001 through 2016, a total of 276,858 active component service members received first-time diagnoses of TBI - a structural alteration of the brain or physiological disruption of brain function caused by an external force.

Recommended Content:

Armed Forces Health Surveillance Division | Medical Surveillance Monthly Report

Rhabdomyolysis by Location, Active Component, U.S. Armed Forces, 2012-2016 Fact Sheet

Fact Sheet
3/30/2017

This fact sheet provides details on Rhabdomyolysis by location for active component, U.S. Armed Forces during a five-year surveillance period from 2012 through 2016. The medical treatment facilities at nine installations diagnosed at least 50 cases each and, together approximately half (49.9%) of all diagnosed cases.

Recommended Content:

Armed Forces Health Surveillance Division | Medical Surveillance Monthly Report

Heat Illnesses by Location, Active Component, U.S. Armed Forces, 2012-2016 Fact Sheet

Fact Sheet
3/30/2017

This fact sheet provides details on heat illnesses by location during a five-year surveillance period from 2012 through 2016. 11,967 heat-related illnesses were diagnosed at more than 250 military installations and geographic locations worldwide. Three Army Installations accounted for close to one-third of all heat illnesses during the period.

Recommended Content:

Armed Forces Health Surveillance Division | Medical Surveillance Monthly Report
<< < ... 11 12 > >> 
Showing results 166 - 179 Page 12 of 12
Refine your search
Last Updated: August 16, 2022
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery